Planning for translational research in genomics

Genome Medicine

Volumn 1, Issue 9, 2009, Pages

  Hawkins, Naomi ^a   De Vries, Jantina ^a   Boddington, Paula ^a   Kaye, Jane ^a   Heeney, Catherine ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACCESS TO INFORMATION; BIOMEDICINE; CLINICAL PRACTICE; COMMERCIAL PHENOMENA; FUNDING; GENOMICS; INFORMED CONSENT; LETTER; MEDICAL RESEARCH; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL;

EID: 77953387231     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm87     Document Type: Letter

References (73)

1. House of Lords, Genomic Medicine Report [http://www. publications.parliament.uk/pa/ld200809/ldselect/ldsctech/107/107i.pdf]
2. Maher B: Personal genomes: The case of the missing heritability. Nature 2008, 456:18-21.
3. Kraft P, Hunter DJ: Genetic risk prediction - are we there yet? N Engl J Med 2009, 360:1701-1703.
4. Goldstein DB: Common genetic variation and human traits. N Engl J Med 2009, 360:1696-1698.
5. Lanktree MB, Hegele RA: Gene-gene and gene-environment interactions: new insights into the prevention, detection and management of coronary artery disease. Genome Med 2009, 1:28.
6. Melzer D, Hogarth S, Liddell K, Ling T, Sanderson S, Zimmern RL: Genetic tests for common diseases: new insights, old concerns. BMJ 2008, 336:590-593.
7. McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, Ioannidis JPA, Hirschhorn JN: Genome-wide association studies for complex traits: consensus, uncertainties, and challenge. Nat Rev Genet 2008, 9:356-359.
8. Holtzman NA, Marteau TM: Will genetics revolutionize medicine? N Engl J Med 2000, 343:141-144.
9. Burke W, Khoury MJ, Stewart A, Zimmern RL: The path from genome-based research to population health: development of an international public health genomics network. Genet Med 2006, 8:451-458.
10. Hirschhorn JN: Genomewide association studies - illuminating biologic pathways. N Engl J Med 2009, 360:1699-1701.
11. Hegele RA: Plasma lipoproteins: genetic influences and clinical implications. Nat Rev Genet 2009, 10:109-121.
12. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R: SLCO1B1 variants and statin-induced myopathy - a genomewide study. N Engl J Med 2008, 359:789-799.
13. Sheffield LJ, Phillimore HE: Clinical use of pharmacogenomic tests in 2009. Clin Biochem Rev 2009, 30:55-65.
14. Lai-Goldman M, Faruki H: Abacavir hypersensitivity: a model system for pharmacogenetic test adoption. Genet Med 2008, 10:874-878.
15. Magnus D, Cho MK, Cook-Deegan R: Direct-to-consumer genetic tests: beyond medical regulation? Genome Med 2009, 1:17.
16. Schickedanz AD, Herdman RC: Direct-to-consumer genetic testing: the need to get retail genomics right. Clin Pharmacol Ther 2009, 86:17-20.
17. Ameer B, Krivoy N: Direct-to-consumer/patient advertising of genetic testing: a position statement of the American College of Clinical Pharmacology. J Clin Pharmacol 2009, 49:886-888.
18. Debouck C: Integrating genomics across drug discovery and development. Toxicol Lett 2009, 186:9-12.
19. Jakobsdottir J, Gorin MB, Conley YP, Ferrell RE, Weeks DE: Interpretation of genetic association studies: markers with replicated highly significant odds ratios may be poor classifiers. PLoS Genet 2009, 5:e1000337.
20. Janssens ACJW, van Duijn CM: Genome-based prediction of common diseases: advances and prospects. Hum Mol Genet 2008, 17:R166-R172.
21. Eckman MH, Rosand J, Greenberg SM, Gage BF: Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Internal Med 2009, 150:73-83.
22. McCarthy MI, Hirschhorn JN: Genome-wide association studies: potential next steps on a genetic journey. Hum Mol Genet 2008, 17:R156-R165.
23. Scheuner MT, Sieverding P, Shekelle PG: Delivery of genomic medicine for common chronic adult diseases: a systematic review. JAMA 2008, 299:1320-1334.
24. Caulfield T, Einsiedel E, Merz JF, Nicol D: Trust, patents and public perceptions: the governance of controversial biotechnology research. Nat Biotechnol 2006, 24:1352-1354.
25. DiMasi JA, Hansen RW, Grabowski HG: The price of innovation: new estimates of drug development costs. J Health Econ 2003, 22: 151-185.
26. Bessen J, Meurer MJ: Patent Failure: How Judges, Bureaucrats, and Lawyers Put Innovators at Risk. Princeton, NJ: Princeton University Press; 2008.
27. Procardis [http://www.procardis.org/]
28. EU Funding Opportunities for Research into Major Diseases [ftp://ftp.cordis.europa.eu/pub/lifescihealth/docs/4th_sme_050524_oib_ bat.pdf]
29. BG Medicine, Framingham Heart Researchers Partner on Cardio Tests [http://www.genomeweb.com/dxpgx/bg-medicine-framinghamheart-researchers- partner-cardio-tests]
30. Working with MRC Technology [http://www.mrctechnology.org/ SCI_Working.htm]
31. Hammang JP: Industry and academia must avoid mismatching disclosures. Nat Biotechnol 2009, 27:21.
32. Thursby JG, Thursby MC: Intellectual property. University licensing and the Bayh-Dole Act. Science 2003, 301:1052.
33. In the Public Interest: Nine Points to Consider in Licensing University Technology [http://news-service.stanford.edu/news/2007/ march7/gifs/whitepaper.pdf]
34. National Institutes of Health: Best Practices for the Licensing of Genomic Inventions. 70 Federal Register 18413; 11 April 2005.
35. Organisation for Economic Co-operation and Development: Guidelines for the Licensing of Genetic Inventions. Organisation for Economic Co-operation and Development; 2006.
36. Lambert Tool Kit for Collaborative Research [http://www.innovation. gov.uk/lambertagreements/index.asp?lvl1=0&lvl2=0&lvl3=0&lvl4 =0]
37. Krattiger AF, Centre for Management of Intellectual Property in Health Research and Development., Public Intellectual Property Resource for Agriculture: Intellectual Property Management in Health and Agricultural Innovation: a Handbook of Best Practices. Oxford: MIHR: PIPRA; 2007.
38. Gold ER, Bubela T: Drafting Effective Collaborative Research Agreements and Related Contracts. In Intellectual Property Management in Health and Agricultural Innovation: a Handbook of Best Practices. Edited by Krattiger AF, Centre for Management of Intellectual Property in Health Research and Development., Public Intellectual Property Resource for Agriculture. Oxford: MIHR: PIPRA; 2007
39. Medical Research Council: MRC Strategic Plan 2004 -2007. London; 2004.
40. Lehrman S: Stanford seeks life after Cohen-Boyer patent expires. Nature 1993, 363:574.
41. Piper T, Gold R: Practices, Policies and Possibilities in Licensing in Human Genetics. The Innovation Partnership for Health Canada; 2008.
42. Schroeder D: Benefit sharing: it's time for a definition. J Med Ethics 2007, 33:205-209.
43. Pullman D, Latus A: Benefit sharing in smaller markets: the case of Newfoundland and Labrador. Community Genet 2003, 6:178-181.
44. Haddow G, Laurie G, Cunningham-Burley S, Hunter KG: Tackling community concerns about commercialisation and genetic research: a modest interdisciplinary proposal. Soc Sci Med 2007, 64:272-282.
45. UK Biobank: What Happens at an Assessment Centre? [http://www.ukbiobank.ac.uk/assessment/whathappens.php]
46. Andanda P: Vulnerability: sex workers in Nairobi's Majengo slum. Camb Q Healthc Ethics 2009, 18:138-146.
47. HUGO Ethics Committee: HUGO Urges Genetic Benefit-sharing. Community Genet 2000, 3:88-92.
48. Forsberg JS, Hansson MG, Eriksson S: Changing perspectives in biobank research: from individual rights to concerns about public health regarding the return of results. Eur J Hum Genet 2009 [Epub ahead of print].
49. Data Release Policy for Genome-wide Association Data [http://www.malariagen.net/home/downloads/16.pdf]
50. Stevens AJ, Effort AE: Using academic license agreements to promote global social responsibility. Les Nouvelles: The Journal of the Licensing Executives Society International 2008, 43:85.
51. Kettis-Lindblad A, Ring L, Viberth E, Hansson MG: Genetic research and donation of tissue samples to biobanks. What do potential sample donors in the Swedish general public think? Eur J Public Health 2005, 16:433-440.
52. Beskow LM, Dean E: Informed consent for biorepositories: assessing prospective participants' understanding and opinions. Cancer Epidemiol Biomarkers Prev 2008, 17:1440-1451.
53. Gene Watch UK [http://www.genewatch.org/]
54. Terry SF, Terry PF, Rauen KA, Uitto J, Bercovitch LG: Advocacy groups as research organizations: the PXE International example. Nat Rev Genet 2007, 8:157-164.
55. Genetic Interest Group [http://www.gig.org.uk/]
56. Press Release: 23andMe Launches Parkinson's Disease Genetics Initiative [https://www.23andme.com/about/press/20090312/]
57. Appelbaum PS, Roth LH, Lidz CW, Benson P, Winslade W: False hopes and best data - consent to research and the therapeutic misconception. Hastings Cent Rep 1987, 17:20-24.
58. Fisher JA: Procedural misconceptions and informed consent: insights from empirical research on the clinical trials industry. Kennedy Inst Ethics J 2006, 16:251-268.
59. Weinfurt KP, Hall MA, Friedman JY, Hardy NC, Fortune-Greeley AK, Lawlor JS, Allsbrook JS, Lin L, Schulman KA, Sugarman J: Effects of disclosing financial interest on participation in medical research: a randomised vignette trial. Am Heart J 2008, 156:689-697.
60. Weinfurt KP, Friedman JY, Allsbrook JS, Dinan MA, Hall MA, Sugarman J: Views of potential research participants on financial conflicts of interest: barriers and opportunities for effective disclosure. J Gen Intern Med 2006, 21:901-906.
61. Kim SYH, Millard RW, Nisbet P, Cox C, Caine ED: Potential research participants' views regarding researcher and institutional financial conflicts of interest. J Med Ethics 2004, 30:73-79.
62. Hoeyer K, Olofsson B-O, Mjorndal T, Lynoe N: Informed consent and biobanks: a population based study of attitudes towards tissue donation for genetic research. Scand J Public Health 2004, 32:224-229.
63. Phase 9 Clinic Consent Form [http://www.ucl.ac.uk/whitehallII/ data_sharing/Phase_9_consent_form.pdf]
64. Consent Form: Example 2 (DNA Sequencing), NHGRI Medical Sequencing Project [http://www.genome.gov/Pages/PolicyEthics/Informed%20Consent/C onsentFormExample2.pdf]
65. P3G Observatory: Kadoorie Study of Chronic Disease in China [KSCDC] [http://www.p3gobservatory.org/catalogue.htm?itVersionId= 4]
66. Chen Z, Liming L, Chen J, Collins R, Wu F, Guo Y: Cohort profile: the Kadoorie Study of chronic disease in China (KSCDC). Int J Epidemiol 2005, 34:1243-1249.
67. Generic Consent Form [http://www.p3gobservatory.org/download/ Modelconsentform_Finalnov6.doc]
68. O'Neill O: Some limits of informed consent. J Med Ethics 2003, 29:4-7.
69. Taylor P: When consent gets in the way. Nature 2008, 456:32.
70. Corbie-Smith G, Thomas SB, Williams MV, Moody-Ayers S: Attitudes and beliefs of African Americans toward participation in medical research. J Gen Int Med 1999, 14:537-5446.
71. Sharp LM, Frankel J: Respondent burden - a test of some common assumptions. Public Opin Quart 1983, 47:36-53.
72. Cooper RS, Tayo B, Zhu X: Genome-wide association studies: implications for multiethnic samples. Hum Mol Genet 2008, 17:R151-155.
73. Epstein S: The rise of `recruitmentology': clinical research, racial knowledge, and the politics of inclusion and difference. Soc Stud Sci 2008, 38:801-832.